首页 > 最新文献

International Journal of Organ Transplantation Medicine最新文献

英文 中文
De-novo Upper Gastrointestinal Tract Cancer after Liver Transplantation: A Demographic Report. 肝移植后再生上消化道肿瘤:一份人口统计报告。
IF 0.7 Q4 TRANSPLANTATION Pub Date : 2020-01-01
E M Dobrindt, M Biebl, S Rademacher, C Denecke, A Andreou, J Raakow, D Kröll, R Öllinger, J Pratschke, S S Chopra

Background: Immunosuppression is essential after liver transplantation (LT). It, however, increases the risk for cancer.

Objective: To evaluate the prevalence and outcome of upper gastrointestinal (GI) tract cancer in LT patients and assess the perioperative risk of surgery for the upper GI malignancies post-LT.

Methods: 2855 patients underwent LT at our clinic from 1988 to 2018. 20 patients developed upper GI cancer. Data were retrospectively extracted from our database. Analysis included patients' specific data, tumor histopathology and stage, the treatment given and survival.

Results: 23 patients developed upper GI malignancies (2 gastric and 18 esophageal cancers; 3 excluded), translating to a incidence of 26.4 per 100,000 population per year. All patients were male. 80% showed alcohol-induced cirrhosis before LT. Most of the tumors were diagnosed at a stage ≥III. 70% underwent surgery and 78.6% developed postoperative complications. One-year-survival was 50%. Total survival rate was 28.6% with a median follow-up of 10 months (range: 0-184).

Conclusion: Upper GI malignancies are more common after LT compared to the general population. Men after LT, due to alcohol-induced liver cirrhosis, are at a higher risk. Upper GI surgery after LT can be safe, but the severe risk for complications and a poor survival require strict indications.

背景:肝移植(LT)后免疫抑制是必要的。然而,它会增加患癌症的风险。目的:了解上消化道肿瘤在肝移植患者中的发病率及转归,探讨肝移植后上消化道肿瘤手术的围手术期风险。方法:1988年至2018年在我院行肝移植的2855例患者。20例患者发生上消化道肿瘤。数据回顾性地从我们的数据库中提取。分析包括患者的具体资料、肿瘤组织病理学和分期、给予的治疗和生存期。结果:23例患者发生上消化道恶性肿瘤(2例胃癌,18例食管癌;3例除外),换算成每年每10万人26.4例的发病率。所有患者均为男性。80%的患者在lt前出现酒精性肝硬化,大部分肿瘤诊断为≥III期。70%接受手术,78.6%出现术后并发症。一年生存率为50%。总生存率为28.6%,中位随访10个月(范围:0-184)。结论:与一般人群相比,上消化道恶性肿瘤在肝移植后更常见。肝移植后的男性,由于酒精性肝硬化,风险更高。肝移植后的上消化道手术是安全的,但严重的并发症风险和较差的生存率需要严格的适应症。
{"title":"<i>De-novo</i> Upper Gastrointestinal Tract Cancer after Liver Transplantation: A Demographic Report.","authors":"E M Dobrindt,&nbsp;M Biebl,&nbsp;S Rademacher,&nbsp;C Denecke,&nbsp;A Andreou,&nbsp;J Raakow,&nbsp;D Kröll,&nbsp;R Öllinger,&nbsp;J Pratschke,&nbsp;S S Chopra","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Immunosuppression is essential after liver transplantation (LT). It, however, increases the risk for cancer.</p><p><strong>Objective: </strong>To evaluate the prevalence and outcome of upper gastrointestinal (GI) tract cancer in LT patients and assess the perioperative risk of surgery for the upper GI malignancies post-LT.</p><p><strong>Methods: </strong>2855 patients underwent LT at our clinic from 1988 to 2018. 20 patients developed upper GI cancer. Data were retrospectively extracted from our database. Analysis included patients' specific data, tumor histopathology and stage, the treatment given and survival.</p><p><strong>Results: </strong>23 patients developed upper GI malignancies (2 gastric and 18 esophageal cancers; 3 excluded), translating to a incidence of 26.4 per 100,000 population per year. All patients were male. 80% showed alcohol-induced cirrhosis before LT. Most of the tumors were diagnosed at a stage ≥III. 70% underwent surgery and 78.6% developed postoperative complications. One-year-survival was 50%. Total survival rate was 28.6% with a median follow-up of 10 months (range: 0-184).</p><p><strong>Conclusion: </strong>Upper GI malignancies are more common after LT compared to the general population. Men after LT, due to alcohol-induced liver cirrhosis, are at a higher risk. Upper GI surgery after LT can be safe, but the severe risk for complications and a poor survival require strict indications.</p>","PeriodicalId":14242,"journal":{"name":"International Journal of Organ Transplantation Medicine","volume":"11 2","pages":"71-80"},"PeriodicalIF":0.7,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38293006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Effect of Monthly Anti-CD25+ Treatment with Basiliximab on the Progression of Chronic Renal Dysfunction after Lung Transplantation. 巴厘昔单抗每月抗cd25 +治疗对肺移植后慢性肾功能障碍进展的影响。
IF 0.7 Q4 TRANSPLANTATION Pub Date : 2020-01-01
D J Ross, J Belperio, C Natori, A Ardehali
<p><strong>Background: </strong>Chronic renal dysfunction (CRD), as predominantly related to calcineurin-inhibitor (CNI) nephrotoxicity, is associated with increased morbidity and mortality after lung transplantation (LTx). Basiliximab (BSX), a recombinant chimeric monoclonal antibody against CD25<sup>+</sup> on activated T-lymphocytes, although often employed as an "induction immunosuppression" after solid organ transplantation, may further allow for reduction in CNI exposure with monthly administration and amelioration of CRD.</p><p><strong>Objective: </strong>To determine the effect of monthly anti-CD25<sup>+</sup> treatment with basiliximab on the progression of chronic renal dysfunction after lung transplantation.</p><p><strong>Methods: </strong>Post-LTx recipients with stages IIIB-V CRD were treated with monthly intravenous infusion of BSX 20 mg. They were analyzed for creatinine clearance at 1, 3, 6, and 12 months; rate of the change in the clearance (the slope of the regression line) and FEV<sub>1</sub>/month; de novo HLA class I or II DSA; and infectious events (IE). Tacrolimus (TAC) trough levels were concurrently targeted at 2-4 ng/mL during BSX therapy. The criteria for BSX discontinuation included acute lung allograft rejection, acute respiratory infection, and progression to end-stage renal disease (ESRD).</p><p><strong>Results: </strong>9 LTx recipients were treated with BSX for ≥6 months. The median time past after their LTx was 1853 (range: 75-7212) days; the mean±SD age was 64.3±11.3 years; the male:female ratio was 7:2. The baseline mean±SD creatinine clearance 1-3 months prior to BSX initiation was 22.8±5.14 mL/min/1.73 m<sup>2</sup> (CI: 3.95) consistent with CRD stages-IIIB (2), IV (6), and V (1). Prior to BSX treatment, all 9 patients had established CLAD-obstructive-phenotype (BOS, n=4) and restrictive-phenotype (RAS, n=5). During the course of BSX treatment, the aggregate creatinine clearance mean slope increased by a mean±SD of 0.747±0.467 mL/min/1.72 m<sup>2</sup>/month (CI: 0.359), consistent with "stabilization" of renal function in 7 patients; deterioration occurred in 2 with transition to chronic hemodialysis. Spirometric stability in lung allograft function was observed in 5 patients with a mean±SD aggregate FEV<sub>1</sub> slope of -1.49±1.08 mL/month (CI: 2.50). 3 deaths occurred due to the following conditions during BSX treatment-HFpEF/Sepsis + CLAD/Parainfluenza type 2 bronchiolitis + CLAD. 2 recipients developed "weak MFI" HLA class II DSA; no HLA class I DSA was detected during the treatment.</p><p><strong>Conclusion: </strong>Renal sparing therapy with monthly BSX infusion with concurrent reduction in CNI exposure (TAC = 2-4 ng/mL) for stages IIIB-V CRD was associated with stability in creatinine clearance in 78% of patients over a treatment course of 6-12 months. Pre-existing CLAD afflicting all patients and inherent variability in progression of chronic rejection, limits our assessment of BSX efficacy in
背景:慢性肾功能障碍(CRD)主要与钙调磷酸酶抑制剂(CNI)肾毒性相关,与肺移植(LTx)后发病率和死亡率增加相关。Basiliximab (BSX)是一种针对活化t淋巴细胞的CD25+的重组嵌合单克隆抗体,虽然经常被用作实体器官移植后的“诱导免疫抑制”,但可以通过每月给药和改善CRD进一步减少CNI暴露。目的:探讨巴厘昔单抗每月抗cd25 +治疗对肺移植术后慢性肾功能障碍进展的影响。方法:接受ltx治疗的IIIB-V期CRD患者每月静脉输注bsx20mg。在1、3、6和12个月时分析他们的肌酐清除率;间隙(回归线斜率)变化率和FEV1/月;新生HLA I类或II类DSA;和传染性事件(IE)。在BSX治疗期间,他克莫司(TAC)谷水平同时靶向为2-4 ng/mL。BSX停药的标准包括急性肺同种异体移植排斥反应、急性呼吸道感染和进展为终末期肾病(ESRD)。结果:9名LTx受者接受BSX治疗≥6个月。其LTx后的中位数时间为1853(范围:75-7212)天;平均±SD年龄为64.3±11.3岁;男女比例为7:2。BSX开始前1-3个月的基线平均±SD肌酐清除率为22.8±5.14 mL/min/1.73 m2 (CI: 3.95),与CRD分期- iiib (2), IV(6)和V(1)相一致。在BSX治疗前,所有9例患者均建立了clad -梗阻性表型(BOS, n=4)和限制性表型(RAS, n=5)。在BSX治疗过程中,总肌酐清除率平均斜率平均±SD增加0.747±0.467 mL/min/1.72 m2/月(CI: 0.359),与7例患者肾功能“稳定”一致;2例病情恶化,转为慢性血液透析。5例患者的FEV1平均±SD累计斜率为-1.49±1.08 mL/月(CI: 2.50)。在BSX治疗期间,有3例死亡发生于以下情况:hfpef /败血症+ CLAD/副流感2型细支气管炎+ CLAD。2例发生“弱MFI”型HLAⅱ类DSA;治疗期间未检测到HLA I类DSA。结论:在6-12个月的治疗过程中,78%的IIIB-V期CRD患者的肌酐清除率稳定与每月输注BSX并同时减少CNI暴露(TAC = 2-4 ng/mL)的肾保留治疗相关。所有患者均存在既往性慢性排斥反应,以及慢性排斥反应进展的内在变异性限制了我们对BSX疗效的评估。我们在BSX治疗期间检测到罕见的新发HLA II类DSA。
{"title":"The Effect of Monthly Anti-CD25<sup>+</sup> Treatment with Basiliximab on the Progression of Chronic Renal Dysfunction after Lung Transplantation.","authors":"D J Ross,&nbsp;J Belperio,&nbsp;C Natori,&nbsp;A Ardehali","doi":"","DOIUrl":"","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Chronic renal dysfunction (CRD), as predominantly related to calcineurin-inhibitor (CNI) nephrotoxicity, is associated with increased morbidity and mortality after lung transplantation (LTx). Basiliximab (BSX), a recombinant chimeric monoclonal antibody against CD25&lt;sup&gt;+&lt;/sup&gt; on activated T-lymphocytes, although often employed as an \"induction immunosuppression\" after solid organ transplantation, may further allow for reduction in CNI exposure with monthly administration and amelioration of CRD.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To determine the effect of monthly anti-CD25&lt;sup&gt;+&lt;/sup&gt; treatment with basiliximab on the progression of chronic renal dysfunction after lung transplantation.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Post-LTx recipients with stages IIIB-V CRD were treated with monthly intravenous infusion of BSX 20 mg. They were analyzed for creatinine clearance at 1, 3, 6, and 12 months; rate of the change in the clearance (the slope of the regression line) and FEV&lt;sub&gt;1&lt;/sub&gt;/month; de novo HLA class I or II DSA; and infectious events (IE). Tacrolimus (TAC) trough levels were concurrently targeted at 2-4 ng/mL during BSX therapy. The criteria for BSX discontinuation included acute lung allograft rejection, acute respiratory infection, and progression to end-stage renal disease (ESRD).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;9 LTx recipients were treated with BSX for ≥6 months. The median time past after their LTx was 1853 (range: 75-7212) days; the mean±SD age was 64.3±11.3 years; the male:female ratio was 7:2. The baseline mean±SD creatinine clearance 1-3 months prior to BSX initiation was 22.8±5.14 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt; (CI: 3.95) consistent with CRD stages-IIIB (2), IV (6), and V (1). Prior to BSX treatment, all 9 patients had established CLAD-obstructive-phenotype (BOS, n=4) and restrictive-phenotype (RAS, n=5). During the course of BSX treatment, the aggregate creatinine clearance mean slope increased by a mean±SD of 0.747±0.467 mL/min/1.72 m&lt;sup&gt;2&lt;/sup&gt;/month (CI: 0.359), consistent with \"stabilization\" of renal function in 7 patients; deterioration occurred in 2 with transition to chronic hemodialysis. Spirometric stability in lung allograft function was observed in 5 patients with a mean±SD aggregate FEV&lt;sub&gt;1&lt;/sub&gt; slope of -1.49±1.08 mL/month (CI: 2.50). 3 deaths occurred due to the following conditions during BSX treatment-HFpEF/Sepsis + CLAD/Parainfluenza type 2 bronchiolitis + CLAD. 2 recipients developed \"weak MFI\" HLA class II DSA; no HLA class I DSA was detected during the treatment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Renal sparing therapy with monthly BSX infusion with concurrent reduction in CNI exposure (TAC = 2-4 ng/mL) for stages IIIB-V CRD was associated with stability in creatinine clearance in 78% of patients over a treatment course of 6-12 months. Pre-existing CLAD afflicting all patients and inherent variability in progression of chronic rejection, limits our assessment of BSX efficacy in ","PeriodicalId":14242,"journal":{"name":"International Journal of Organ Transplantation Medicine","volume":"11 3","pages":"101-106"},"PeriodicalIF":0.7,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38366043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges in the Management of Care of Brain-Dead Patients in the Donation Process: A Qualitative Content Analysis. 捐赠过程中脑死亡患者护理管理面临的挑战:定性内容分析。
IF 0.7 Q4 TRANSPLANTATION Pub Date : 2020-01-01
H YazdiMoghaddam, Z S Manzari, A Heydari, E Mohammadi

Background: In care of brain-dead patients, nurses face several challenges. It is important to determine the context behind these challenges since they affect the performance of nurses and the organ donation process.

Objective: To identify factors affecting the emergence of challenges related to the management of brain-dead patients by nurses in the donation process.

Methods: In this qualitative conventional content analysis, data were collected by performing 28 semi-structured and in-depth interviews with nurses working in the ICUs. Purposive sampling started from March 2014 until saturation, which was reached in June 2016. Data analysis occurred simultaneously with data collection.

Results: Qualitative analysis of contents provided from interviews led to the extraction of themes that showed the experience of nurses about the challenges of caring for brain-dead patients in the donation process. These themes included "doubt and conflict in accepting the situation" and "defects in an effective and targeted care system." In the end, the main theme of "inconsistency and incompatibility of care management" was abstracted.

Conclusion: According to the results of the study, factors involved in the emergence of challenges for nurses in care management included defects in education or managerial problems, which increased tension for nurses.

背景:在护理脑死亡患者的过程中,护士面临着一些挑战。确定这些挑战背后的背景非常重要,因为它们会影响护士的表现和器官捐献过程:确定影响护士在捐献过程中管理脑死亡患者相关挑战出现的因素:在这项定性常规内容分析中,通过对重症监护室的护士进行 28 次半结构化深入访谈收集数据。有目的抽样从 2014 年 3 月开始,直到 2016 年 6 月达到饱和。数据分析与数据收集同时进行:通过对访谈内容进行定性分析,得出了一些主题,这些主题显示了护士在捐赠过程中护理脑死亡患者所面临挑战的经验。这些主题包括 "接受这种情况时的疑虑和冲突 "以及 "有效和有针对性的护理系统的缺陷"。最后,抽象出 "护理管理的不一致性和不兼容性 "这一主题:根据研究结果,护士在护理管理中面临挑战的因素包括教育缺陷或管理问题,这加剧了护士的紧张感。
{"title":"Challenges in the Management of Care of Brain-Dead Patients in the Donation Process: A Qualitative Content Analysis.","authors":"H YazdiMoghaddam, Z S Manzari, A Heydari, E Mohammadi","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>In care of brain-dead patients, nurses face several challenges. It is important to determine the context behind these challenges since they affect the performance of nurses and the organ donation process.</p><p><strong>Objective: </strong>To identify factors affecting the emergence of challenges related to the management of brain-dead patients by nurses in the donation process.</p><p><strong>Methods: </strong>In this qualitative conventional content analysis, data were collected by performing 28 semi-structured and in-depth interviews with nurses working in the ICUs. Purposive sampling started from March 2014 until saturation, which was reached in June 2016. Data analysis occurred simultaneously with data collection.</p><p><strong>Results: </strong>Qualitative analysis of contents provided from interviews led to the extraction of themes that showed the experience of nurses about the challenges of caring for brain-dead patients in the donation process. These themes included \"doubt and conflict in accepting the situation\" and \"defects in an effective and targeted care system.\" In the end, the main theme of \"inconsistency and incompatibility of care management\" was abstracted.</p><p><strong>Conclusion: </strong>According to the results of the study, factors involved in the emergence of challenges for nurses in care management included defects in education or managerial problems, which increased tension for nurses.</p>","PeriodicalId":14242,"journal":{"name":"International Journal of Organ Transplantation Medicine","volume":"11 3","pages":"129-142"},"PeriodicalIF":0.7,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38366047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 and Organ Transplantation? COVID-19与器官移植?
IF 0.7 Q4 TRANSPLANTATION Pub Date : 2020-01-01
A Zomorrodi
{"title":"COVID-19 and Organ Transplantation?","authors":"A Zomorrodi","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":14242,"journal":{"name":"International Journal of Organ Transplantation Medicine","volume":"11 3","pages":"143-144"},"PeriodicalIF":0.7,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38366048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Survey of Nephrologists Regarding Their Communication with Transplant Centers. 肾科医师与移植中心沟通的调查。
IF 0.7 Q4 TRANSPLANTATION Pub Date : 2020-01-01
K Bartolomeo, M Lipinski, J Romeu, N Ghahramani

Background: Patients with end-stage renal disease (ESRD) undergo a transition of care between their primary nephrologist and the transplant center during evaluation for kidney transplantation. Due to medical complexity, high hospitalization rate, and involvement of multiple medical stakeholders, transitions of medical care among patients with ESRD are likely to be associated with suboptimal care and medical errors. Provider-to-provider communication improves outcomes among ESRD patients transitioning between dialysis and transplant. There is little data analyzing proper transition of care between the nephrologist and the transplant center (TC).

Objective: Using survey methodology, we examined nephrologists' current practice and experience regarding patient-related communication with the TC.

Methods: From among 822 nephrologists who were following at least 20 ESRD patients, we randomly selected 252 nephrologists to participate in the study. The survey consisted of 102 multiple choice and Likert-style items probing perceptions about various aspects of transplant, including communication between TC and nephrologist. Responses from 216 participants who submitted complete responses were included in the final analysis.

Results: Depending on the phase of transplant, nephrologist-TC communication varied between 50%-81% of nephrologists. Factors associated with higher likelihood of nephrologist-TC communication included attending transplant-related educational activity, practicing in a group with more than 5 nephrologists, and having more than 50 patients on dialysis. The majority of nephrologists indicated satisfaction with access to an attending physician in the TC, receiving timely and adequate information from the TC about their patients. Factors associated with higher likelihood of nephrologist satisfaction regarding communication with the TC included attending national nephrology meetings, medical directorship of a dialysis unit, fellowship training at an institution with an on-site transplant program, and availability of more than 2 transplant centers within 50 miles.

Conclusion: There is a lack of evidence-based guidelines for patient transfer of care between nephrologists and transplant centers during various phases of transplant referral, evaluation and post-transplant care. We found that the likelihood of the nephrologists' communication with the transplant center and their satisfaction with the communication are related to their training, participation in continuing educational meetings, their practice location and size, and the overall composition of their patient population.

背景:终末期肾病(ESRD)患者在进行肾移植评估时,经历了在原肾科医生和移植中心之间的护理过渡。由于医疗复杂性、高住院率和涉及多个医疗利益相关者,ESRD患者的医疗护理转变可能与次优护理和医疗差错有关。提供者与提供者之间的沟通改善了从透析到移植的ESRD患者的预后。很少有数据分析肾科医生和移植中心(TC)之间护理的适当过渡。目的:采用问卷调查的方法,我们检查肾脏科医生目前的做法和经验,在患者相关的沟通与TC。方法:从随访至少20例ESRD患者的822名肾病学家中,我们随机选择252名肾病学家参与研究。调查包括102个多项选择题和李克特式题,探讨对移植的各个方面的看法,包括TC和肾病专家之间的沟通。216名参与者提交了完整的回答,他们的回答被纳入最终分析。结果:根据移植的不同阶段,肾内科医生与tc的沟通在50%-81%之间。与肾内科医生与tc沟通的可能性较高的因素包括参加与移植相关的教育活动,在一个有5名以上肾内科医生的小组中执业,以及有50名以上的透析患者。大多数肾科医生表示,他们对与TC的主治医师接触感到满意,并从TC获得有关患者的及时和充分的信息。在与TC沟通方面,肾病专家满意度较高的因素包括参加国家肾病学会议、透析部门的医疗主管、在有现场移植项目的机构接受奖学金培训,以及50英里内有2个以上移植中心。结论:在移植转诊、评估和移植后护理的各个阶段,肾脏科医生和移植中心之间的患者转移护理缺乏循证指南。我们发现,肾病学家与移植中心沟通的可能性以及他们对沟通的满意度与他们的培训、参与继续教育会议、他们的执业地点和规模以及他们的患者群体的总体构成有关。
{"title":"A Survey of Nephrologists Regarding Their Communication with Transplant Centers.","authors":"K Bartolomeo,&nbsp;M Lipinski,&nbsp;J Romeu,&nbsp;N Ghahramani","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Patients with end-stage renal disease (ESRD) undergo a transition of care between their primary nephrologist and the transplant center during evaluation for kidney transplantation. Due to medical complexity, high hospitalization rate, and involvement of multiple medical stakeholders, transitions of medical care among patients with ESRD are likely to be associated with suboptimal care and medical errors. Provider-to-provider communication improves outcomes among ESRD patients transitioning between dialysis and transplant. There is little data analyzing proper transition of care between the nephrologist and the transplant center (TC).</p><p><strong>Objective: </strong>Using survey methodology, we examined nephrologists' current practice and experience regarding patient-related communication with the TC.</p><p><strong>Methods: </strong>From among 822 nephrologists who were following at least 20 ESRD patients, we randomly selected 252 nephrologists to participate in the study. The survey consisted of 102 multiple choice and Likert-style items probing perceptions about various aspects of transplant, including communication between TC and nephrologist. Responses from 216 participants who submitted complete responses were included in the final analysis.</p><p><strong>Results: </strong>Depending on the phase of transplant, nephrologist-TC communication varied between 50%-81% of nephrologists. Factors associated with higher likelihood of nephrologist-TC communication included attending transplant-related educational activity, practicing in a group with more than 5 nephrologists, and having more than 50 patients on dialysis. The majority of nephrologists indicated satisfaction with access to an attending physician in the TC, receiving timely and adequate information from the TC about their patients. Factors associated with higher likelihood of nephrologist satisfaction regarding communication with the TC included attending national nephrology meetings, medical directorship of a dialysis unit, fellowship training at an institution with an on-site transplant program, and availability of more than 2 transplant centers within 50 miles.</p><p><strong>Conclusion: </strong>There is a lack of evidence-based guidelines for patient transfer of care between nephrologists and transplant centers during various phases of transplant referral, evaluation and post-transplant care. We found that the likelihood of the nephrologists' communication with the transplant center and their satisfaction with the communication are related to their training, participation in continuing educational meetings, their practice location and size, and the overall composition of their patient population.</p>","PeriodicalId":14242,"journal":{"name":"International Journal of Organ Transplantation Medicine","volume":"11 3","pages":"95-100"},"PeriodicalIF":0.7,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471615/pdf/ijotm-11-095.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38368152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug-Drug Interactions among Kidney Transplant Recipients in The Outpatient Setting. 门诊肾移植受者的药物相互作用。
IF 0.7 Q4 TRANSPLANTATION Pub Date : 2020-01-01
O Moradi, I Karimzadeh, D Davani-Davari, M Shafiekhani, M M Sagheb, G A Raees-Jalali

Background: Number of patients undergoing kidney transplantation is ever increasing. Drug-drug interactions (DDIs) can complicate transplant patient's treatment course.

Objective: To investigate patterns and factors associated with potential DDIs in kidney transplant recipients under maintenance immunosuppressive regimen at a referral transplantation center in Shiraz, Iran.

Methods: 390 eligible kidney transplant outpatients referred to Motahhari clinic and one of the attending nephrologist's private office during an18-month period were assessed for DDIs. Using the Lexi-Interact online drug interactions software, the prescribed drugs were assessed for the number and type of potential DDIs. Only type D and X interactions were considered eligible for inclusion.

Results: During the study period, 344 DDIs were detected of which, 290 were type D; 54 were type XDDIs. 81% of the detected DDIs were pharmacokinetics. Interaction between cyclosporine + mycophenolic acid (32.3%) was the most frequent DDIs followed by cyclosporine + atorvastatin (11.3%). Immunosuppressant (43.44%) was the most frequently used medication responsible for DDIs. Number of co-administered medications (OR: 1.34, 95% CI: 1.12-1.51) and cyclosporine as main immunosuppressive main drug (OR: 10.43, 95% CI: 6.24-17.42) were identified as independent risk factors for DDIs.

Conclusion: Major DDIs were common in kidney transplant recipients. Considering the importance of DDIs in kidney transplant patients, more attention is warranted in this regard by health care members, especially physicians and pharmacists.

背景:肾移植患者数量不断增加。药物相互作用(ddi)会使移植患者的治疗过程复杂化。目的:研究伊朗设拉子某转诊移植中心维持免疫抑制方案肾移植受者潜在ddi的模式和相关因素。方法:在18个月的时间里,390例符合条件的肾移植门诊患者转介到Motahhari诊所和一位主治肾科医生的私人办公室进行ddi评估。使用Lexi-Interact在线药物相互作用软件,评估处方药物潜在ddi的数量和类型。只有D型和X型相互作用被认为符合纳入条件。结果:研究期间共检出ddi 344例,其中D型290例;54例为xddi型。81%的ddi检测结果为药代动力学。环孢素+霉酚酸(32.3%)是最常见的ddi,其次是环孢素+阿托伐他汀(11.3%)。免疫抑制剂(43.44%)是导致ddi的最常用药物。共给药数量(OR: 1.34, 95% CI: 1.12-1.51)和环孢素作为主要免疫抑制药物(OR: 10.43, 95% CI: 6.24-17.42)被确定为ddi的独立危险因素。结论:重度ddi在肾移植受者中较为常见。考虑到ddi在肾移植患者中的重要性,医疗保健人员,特别是医生和药剂师应该更多地关注这方面的问题。
{"title":"Drug-Drug Interactions among Kidney Transplant Recipients in The Outpatient Setting.","authors":"O Moradi,&nbsp;I Karimzadeh,&nbsp;D Davani-Davari,&nbsp;M Shafiekhani,&nbsp;M M Sagheb,&nbsp;G A Raees-Jalali","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Number of patients undergoing kidney transplantation is ever increasing. Drug-drug interactions (DDIs) can complicate transplant patient's treatment course.</p><p><strong>Objective: </strong>To investigate patterns and factors associated with potential DDIs in kidney transplant recipients under maintenance immunosuppressive regimen at a referral transplantation center in Shiraz, Iran.</p><p><strong>Methods: </strong>390 eligible kidney transplant outpatients referred to Motahhari clinic and one of the attending nephrologist's private office during an18-month period were assessed for DDIs. Using the Lexi-Interact online drug interactions software, the prescribed drugs were assessed for the number and type of potential DDIs. Only type D and X interactions were considered eligible for inclusion.</p><p><strong>Results: </strong>During the study period, 344 DDIs were detected of which, 290 were type D; 54 were type XDDIs. 81% of the detected DDIs were pharmacokinetics. Interaction between cyclosporine + mycophenolic acid (32.3%) was the most frequent DDIs followed by cyclosporine + atorvastatin (11.3%). Immunosuppressant (43.44%) was the most frequently used medication responsible for DDIs. Number of co-administered medications (OR: 1.34, 95% CI: 1.12-1.51) and cyclosporine as main immunosuppressive main drug (OR: 10.43, 95% CI: 6.24-17.42) were identified as independent risk factors for DDIs.</p><p><strong>Conclusion: </strong>Major DDIs were common in kidney transplant recipients. Considering the importance of DDIs in kidney transplant patients, more attention is warranted in this regard by health care members, especially physicians and pharmacists.</p>","PeriodicalId":14242,"journal":{"name":"International Journal of Organ Transplantation Medicine","volume":"11 4","pages":"185-195"},"PeriodicalIF":0.7,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726842/pdf/ijotm-11-185.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38726647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Systematic Review of Donor Serum Sodium Level and Its Impact on Transplant Recipients. 供体血清钠水平及其对移植受者影响的系统综述。
IF 0.7 Q4 TRANSPLANTATION Pub Date : 2020-01-01
J Basmaji, L Hornby, B Rochwerg, P Luke, I M Ball

Background: An important aspect of donor management is the optimization of serum sodium levels.

Objective: To perform a systematic review to determine the effects of donor sodium levels on heart, lung, kidney, and pancreas graft function, recipient mortality, and to identify the optimal donor serum sodium target.

Methods: We searched MEDLINE, Cochrane, Guideline databases, and trial registries from 1946 to May 2019 for studies investigating the effects of donor serum sodium levels on transplant outcomes in all non-hepatic organs. A two-step independent review process was used to identify relevant articles based on inclusion/exclusion criteria. We describe the results narratively, assess the risk of bias, and apply GRADE methodology to evaluate the certainty in the evidence.

Results: We included 18 cohort studies in our final analysis (n=28,007). 3 of 4 studies demonstrated an association between donor serum sodium and successful organ transplantation. 5 studies reported no association with graft function, while 6 studies did. 5 studies reported on recipient survival, 3 of which suggested donor sodium is unlikely to be associated with recipient survival. The included studies had serious risk of bias, and the certainty in evidence was deemed to be very low.

Conclusion: In low risk of bias studies, donor sodium dysregulation is unlikely to affect kidney graft function or mortality of heart and kidney recipients, but the certainty in the evidence is very low due to inconsistency and imprecision. Further research is required to refine the serum sodium target range, quantify the dose-response curve, and identify organs most vulnerable to sodium dysregulation.

背景:优化血清钠水平是献血者管理的一个重要方面。目的:通过系统回顾研究供体钠水平对心脏、肺、肾和胰腺移植功能及受体死亡率的影响,并确定最佳供体血清钠目标。方法:我们检索了MEDLINE、Cochrane、guidelines数据库和1946年至2019年5月的试验注册库,以调查供体血清钠水平对所有非肝器官移植结果的影响。采用两步独立审查程序,根据纳入/排除标准确定相关文章。我们对结果进行叙述性描述,评估偏倚风险,并应用GRADE方法评估证据的确定性。结果:我们在最终分析中纳入了18项队列研究(n=28,007)。4项研究中有3项表明供体血清钠与器官移植成功之间存在关联。5项研究报告与移植物功能无关,6项研究报告与移植物功能有关。5项研究报告了受体的生存,其中3项表明供体钠不太可能与受体生存相关。纳入的研究存在严重的偏倚风险,证据的确定性被认为非常低。结论:在低风险偏倚研究中,供体钠调节异常不太可能影响移植肾功能或心脏和肾脏受体的死亡率,但由于不一致和不精确,证据的确定性非常低。进一步的研究需要细化血清钠的靶范围,量化剂量-反应曲线,并确定最易受钠失调影响的器官。
{"title":"A Systematic Review of Donor Serum Sodium Level and Its Impact on Transplant Recipients.","authors":"J Basmaji,&nbsp;L Hornby,&nbsp;B Rochwerg,&nbsp;P Luke,&nbsp;I M Ball","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>An important aspect of donor management is the optimization of serum sodium levels.</p><p><strong>Objective: </strong>To perform a systematic review to determine the effects of donor sodium levels on heart, lung, kidney, and pancreas graft function, recipient mortality, and to identify the optimal donor serum sodium target.</p><p><strong>Methods: </strong>We searched MEDLINE, Cochrane, Guideline databases, and trial registries from 1946 to May 2019 for studies investigating the effects of donor serum sodium levels on transplant outcomes in all non-hepatic organs. A two-step independent review process was used to identify relevant articles based on inclusion/exclusion criteria. We describe the results narratively, assess the risk of bias, and apply GRADE methodology to evaluate the certainty in the evidence.</p><p><strong>Results: </strong>We included 18 cohort studies in our final analysis (n=28,007). 3 of 4 studies demonstrated an association between donor serum sodium and successful organ transplantation. 5 studies reported no association with graft function, while 6 studies did. 5 studies reported on recipient survival, 3 of which suggested donor sodium is unlikely to be associated with recipient survival. The included studies had serious risk of bias, and the certainty in evidence was deemed to be very low.</p><p><strong>Conclusion: </strong>In low risk of bias studies, donor sodium dysregulation is unlikely to affect kidney graft function or mortality of heart and kidney recipients, but the certainty in the evidence is very low due to inconsistency and imprecision. Further research is required to refine the serum sodium target range, quantify the dose-response curve, and identify organs most vulnerable to sodium dysregulation.</p>","PeriodicalId":14242,"journal":{"name":"International Journal of Organ Transplantation Medicine","volume":"11 2","pages":"43-54"},"PeriodicalIF":0.7,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430057/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38293605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Three Consequent Pediatric Liver Transplant Deaths in the COVID-19 Era. 新冠肺炎时代三例儿童肝移植死亡
IF 0.7 Q4 TRANSPLANTATION Pub Date : 2020-01-01
A Imam, C Karatas, R Imam, A Armutlu, N Mecit, A Karakaya, M Kalayoglu, T Kanmaz

The effect of COVID-19 on the transplant recipients is not well-established. Many reports underestimate the effect of COVID-19 on the immunosuppressed population. Herein, we report on 3 pediatric liver transplant recipients who were transplanted at our center between February 11 and March 10, 2020-during the COVID-19 pandemic era. The 3 patients aged between 5 and 10 months, had a rapid and aggressive respiratory deterioration that necessitated mechanical ventilation and extracorporeal life support; and eventually died. The clinical and pathological pictures likely represent COVID-19 pneumonia. Chest x-rays showed progressive infiltrates. Lung autopsies showed diffuse alveolar damage in two cases. We concluded that COVID-19 is very likely to have catastrophic effects on transplant recipients.

COVID-19对移植受者的影响尚未确定。许多报告低估了COVID-19对免疫抑制人群的影响。在此,我们报告了2020年2月11日至3月10日期间在我中心接受肝移植的3名儿童肝移植受者-在COVID-19大流行时期。3例患者年龄在5 ~ 10个月之间,呼吸系统迅速恶化,需要机械通气和体外生命支持;最后死了。临床和病理表现可能为COVID-19肺炎。胸部x光片显示进行性浸润。两例肺解剖显示弥漫性肺泡损伤。我们的结论是,COVID-19很可能对移植受者产生灾难性的影响。
{"title":"Three Consequent Pediatric Liver Transplant Deaths in the COVID-19 Era.","authors":"A Imam,&nbsp;C Karatas,&nbsp;R Imam,&nbsp;A Armutlu,&nbsp;N Mecit,&nbsp;A Karakaya,&nbsp;M Kalayoglu,&nbsp;T Kanmaz","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The effect of COVID-19 on the transplant recipients is not well-established. Many reports underestimate the effect of COVID-19 on the immunosuppressed population. Herein, we report on 3 pediatric liver transplant recipients who were transplanted at our center between February 11 and March 10, 2020-during the COVID-19 pandemic era. The 3 patients aged between 5 and 10 months, had a rapid and aggressive respiratory deterioration that necessitated mechanical ventilation and extracorporeal life support; and eventually died. The clinical and pathological pictures likely represent COVID-19 pneumonia. Chest x-rays showed progressive infiltrates. Lung autopsies showed diffuse alveolar damage in two cases. We concluded that COVID-19 is very likely to have catastrophic effects on transplant recipients.</p>","PeriodicalId":14242,"journal":{"name":"International Journal of Organ Transplantation Medicine","volume":"11 4","pages":"202-206"},"PeriodicalIF":0.7,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726841/pdf/ijotm-11-202.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38724117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatopulmonary Syndrome and Post-Liver Transplantation Complications: A Case-Control Study. 肝肺综合征和肝移植后并发症:一项病例对照研究。
IF 0.7 Q4 TRANSPLANTATION Pub Date : 2020-01-01
A Morvan, M Gazon, S Duperret, Z Schmitt, P Pradat, K Mohkam, F Aubrun

Background: Although liver transplantation (LT) improves survival in cirrhotic patients with hepatopulmonary syndrome (HPS), few data exist concerning post-operative complications in these patients.

Objective: To compare complications after LT between patients with and without HPS.

Methods: In a case-control study, we retrospectively analyzed all patients who underwent LT in our center from January 2010 to July 2016. We compared cases of identified HPS to controls matched for age, MELD score, comorbidities, red blood cells transfused, and highest dosage of norepinephrine perfused during transplantation.

Results: Among 451 transplanted patients, we identified 71 patients with HPS who could be analyzed. We found a significantly (p<0.001) higher number of post-operative complications in patients with HPS (median 5 vs 3), with more occurrence of cardiac, infectious and surgical complications than in the controls: 39.4% vs 12.7% (p<0.001), 81.7% vs 49.3% (p<0.001), and 59.2% vs 40.1% (p<0.029), respectively. There were also more ICU readmissions at 1 month among HPS patients (10 vs 1, p=0.01). There was no significant difference concerning ventilation data, lengths of ICU or hospital stay (8.5 [range 3-232] and 32 [14-276] days, respectively on the whole cohort) and death in the ICU (4.2% on the whole cohort). The 1-year survival was higher in HPS patients (94.4% vs 81.1%, p=0.034); there was no difference in 5-year survival.

Conclusion: HPS patients seem to have a higher number of complications in the first month following LT.

背景:虽然肝移植(LT)可以提高肝硬化肝肺综合征(HPS)患者的生存率,但很少有关于这些患者术后并发症的数据。目的:比较HPS患者和非HPS患者肝移植术后并发症。方法:在一项病例对照研究中,我们回顾性分析了2010年1月至2016年7月在本中心接受肝移植的所有患者。我们比较了年龄、MELD评分、合并症、红细胞输注和移植过程中灌注去甲肾上腺素的最高剂量相匹配的HPS病例和对照组。结果:在451例移植患者中,我们确定了71例可分析的HPS患者。我们发现(pvs3),心脏、感染和手术并发症的发生率比对照组高:39.4%比12.7% (pvs49.3%) (pvs40.1% (pvs1, p=0.01)。通气数据、ICU时间或住院时间(全队列分别为8.5天[范围3-232]和32天[14-276])和ICU死亡(全队列为4.2%)方面无显著差异。HPS患者的1年生存率较高(94.4% vs 81.1%, p=0.034);5年生存率无差异。结论:HPS患者在肝移植后的第一个月似乎有更多的并发症。
{"title":"Hepatopulmonary Syndrome and Post-Liver Transplantation Complications: A Case-Control Study.","authors":"A Morvan,&nbsp;M Gazon,&nbsp;S Duperret,&nbsp;Z Schmitt,&nbsp;P Pradat,&nbsp;K Mohkam,&nbsp;F Aubrun","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Although liver transplantation (LT) improves survival in cirrhotic patients with hepatopulmonary syndrome (HPS), few data exist concerning post-operative complications in these patients.</p><p><strong>Objective: </strong>To compare complications after LT between patients with and without HPS.</p><p><strong>Methods: </strong>In a case-control study, we retrospectively analyzed all patients who underwent LT in our center from January 2010 to July 2016. We compared cases of identified HPS to controls matched for age, MELD score, comorbidities, red blood cells transfused, and highest dosage of norepinephrine perfused during transplantation.</p><p><strong>Results: </strong>Among 451 transplanted patients, we identified 71 patients with HPS who could be analyzed. We found a significantly (p<0.001) higher number of post-operative complications in patients with HPS (median 5 <i>vs</i> 3), with more occurrence of cardiac, infectious and surgical complications than in the controls: 39.4% <i>vs</i> 12.7% (p<0.001), 81.7% <i>vs</i> 49.3% (p<0.001), and 59.2% <i>vs</i> 40.1% (p<0.029), respectively. There were also more ICU readmissions at 1 month among HPS patients (10 <i>vs</i> 1, p=0.01). There was no significant difference concerning ventilation data, lengths of ICU or hospital stay (8.5 [range 3-232] and 32 [14-276] days, respectively on the whole cohort) and death in the ICU (4.2% on the whole cohort). The 1-year survival was higher in HPS patients (94.4% <i>vs</i> 81.1%, p=0.034); there was no difference in 5-year survival.</p><p><strong>Conclusion: </strong>HPS patients seem to have a higher number of complications in the first month following LT.</p>","PeriodicalId":14242,"journal":{"name":"International Journal of Organ Transplantation Medicine","volume":"11 4","pages":"166-175"},"PeriodicalIF":0.7,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726840/pdf/ijotm-11-166.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38726645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of Different Cold Preservation Solutions on the Functions of Cultured Isolated Human Hepatocytes. 不同低温保存液对人肝细胞功能的影响。
IF 0.7 Q4 TRANSPLANTATION Pub Date : 2020-01-01
M Hossein Aghdaie, N Azarpira, A Shamsaeefar, N Motazedian, M Kaviani, E Esfandiari, S Golbabapour, S Nikeghbalian, K Kazemi, H Salahi, S A Malek-Hosseini, B Geramizadeh

Background: Hepatocyte transplantation using isolated human hepatocytes is an alternative source that can be used for the treatment of metabolic diseases and acute liver failure as a time bridge to liver transplantation. These cells can also be used for bioartificial liver systems and in vitro study of drug toxicity.

Objective: To determine which cold preservation solution is better maintain the liver function.

Methods: We prepared 4 cold preservation solutions made of different combination of antioxidants, chelating, membrane protective, and anti-apoptotic agents as well as inhibitor of cyclophilin D. For hepatocyte isolation, we used livers obtained from unused deceased donor livers and the liver of patients with Crigler-Najjar syndrome who were candidates of partial liver transplantation. After culture and cold preservation, the level of albumin, and urea production were measured as indices of liver functionality.

Results: We found that albumin production significantly decreased after cold preservation in solution 1. There was no significant difference in urea production after cold preservation in solution 1 compared with control 24 h. No significant differences in albumin production were found after cold storage in solution 2 and solution 4 compared with control 24 h. Urea production significantly decreased after cold storage in solutions 2 and 4 compared with control 24 h. As a whole albumin and urea production were significantly decreased after cold preservation. Although albumin and urea production were decreased after cold preservation, but the results of albumin production of two solutions were not significantly different from that of the control group (p=0.109 and 0.951).

Conclusion: Cold preservation of cultured human hepatocytes in solution 2 and solution 4 could maintain the function of albumin production better than other cold preservation solutions in our experiments; solution 1 was more effective on urea production of cultured human hepatocytes at 4 °C for 24 h. To determine if these hepatocytes are suitable candidates for transplantation, further studies should be performed.

背景:利用分离的人肝细胞进行肝细胞移植是治疗代谢性疾病和急性肝衰竭的一种替代来源,可作为肝移植的时间桥梁。这些细胞也可用于生物人工肝系统和体外药物毒性研究。目的:确定哪种低温保存液能较好地维持肝功能。方法:制备4种由抗氧化剂、螯合剂、膜保护剂、抗凋亡剂和亲环蛋白d抑制剂不同组合组成的冷保存液。肝细胞分离采用未使用的已故供体肝脏和部分肝移植候选Crigler-Najjar综合征患者的肝脏。经培养和冷保存后,测定白蛋白水平和尿素产量作为肝功能指标。结果:我们发现,在溶液1中冷藏后,白蛋白的产生明显减少。溶液1冷藏24 h后尿素产量与对照无显著差异,溶液2和溶液4冷藏24 h后白蛋白产量与对照无显著差异,溶液2和溶液4冷藏24 h后尿素产量显著降低,整体而言,冷藏后白蛋白和尿素产量显著降低。冷冻保存后,虽然白蛋白和尿素产量降低,但两种溶液的白蛋白产量与对照组无显著差异(p=0.109和0.951)。结论:培养的人肝细胞冷保存液2和4比其他冷保存液能更好地维持白蛋白生成功能;溶液1对培养的人肝细胞在4°C下24小时的尿素生成更有效。为了确定这些肝细胞是否适合移植,需要进行进一步的研究。
{"title":"Effects of Different Cold Preservation Solutions on the Functions of Cultured Isolated Human Hepatocytes.","authors":"M Hossein Aghdaie,&nbsp;N Azarpira,&nbsp;A Shamsaeefar,&nbsp;N Motazedian,&nbsp;M Kaviani,&nbsp;E Esfandiari,&nbsp;S Golbabapour,&nbsp;S Nikeghbalian,&nbsp;K Kazemi,&nbsp;H Salahi,&nbsp;S A Malek-Hosseini,&nbsp;B Geramizadeh","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Hepatocyte transplantation using isolated human hepatocytes is an alternative source that can be used for the treatment of metabolic diseases and acute liver failure as a time bridge to liver transplantation. These cells can also be used for bioartificial liver systems and <i>in vitro</i> study of drug toxicity.</p><p><strong>Objective: </strong>To determine which cold preservation solution is better maintain the liver function.</p><p><strong>Methods: </strong>We prepared 4 cold preservation solutions made of different combination of antioxidants, chelating, membrane protective, and anti-apoptotic agents as well as inhibitor of cyclophilin D. For hepatocyte isolation, we used livers obtained from unused deceased donor livers and the liver of patients with Crigler-Najjar syndrome who were candidates of partial liver transplantation. After culture and cold preservation, the level of albumin, and urea production were measured as indices of liver functionality.</p><p><strong>Results: </strong>We found that albumin production significantly decreased after cold preservation in solution 1. There was no significant difference in urea production after cold preservation in solution 1 compared with control 24 h. No significant differences in albumin production were found after cold storage in solution 2 and solution 4 compared with control 24 h. Urea production significantly decreased after cold storage in solutions 2 and 4 compared with control 24 h. As a whole albumin and urea production were significantly decreased after cold preservation. Although albumin and urea production were decreased after cold preservation, but the results of albumin production of two solutions were not significantly different from that of the control group (p=0.109 and 0.951).</p><p><strong>Conclusion: </strong>Cold preservation of cultured human hepatocytes in solution 2 and solution 4 could maintain the function of albumin production better than other cold preservation solutions in our experiments; solution 1 was more effective on urea production of cultured human hepatocytes at 4 °C for 24 h. To determine if these hepatocytes are suitable candidates for transplantation, further studies should be performed.</p>","PeriodicalId":14242,"journal":{"name":"International Journal of Organ Transplantation Medicine","volume":"11 1","pages":"15-25"},"PeriodicalIF":0.7,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724769/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38377181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Organ Transplantation Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1